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Background: Metastatic spread of tumor cells remains a serious problem in cancer treatment. Gene-directed enzyme/
prodrug therapy mediated by tumor-homing genetically engineered mesenchymal stromal cells (MSC) represents a
promising therapeutic modality for elimination of disseminated cells. Efficacy of gene-directed enzyme/prodrug therapy
can be improved by combination of individual systems. We aimed to define the combination effect of two systems of
gene therapy mediated by MSC, and evaluate the ability of systemically administered genetically engineered
mesenchymal stromal cells to inhibit the growth of experimental metastases derived from human breast adenocarcinoma
cells MDA-MB-231/EGFP.
Methods: Human adipose tissue-derived mesenchymal stromal cells (AT-MSC) were retrovirally transduced with fusion
yeast cytosine deaminase::uracil phosphoribosyltransferase (CD::UPRT) or with Herpes simplex virus thymidine kinase (HSVtk).
Engineered MSC were cocultured with tumor cells in the presence of prodrugs 5-fluorocytosin (5-FC) and ganciclovir
(GCV). Combination effect of these enzyme/prodrug approaches was calculated. SCID/bg mice bearing experimental
lung metastases were treated with CD::UPRT-MSC, HSVtk-MSC or both in combination in the presence of respective
prodrug(s). Treatment efficiency was evaluated by EGFP-positive cell detection by flow cytometry combined with
real-time PCR quantification of human cells in mouse organs. Results were confirmed by histological and
immunohistochemical examination.
Results: We demonstrated various extent of synergy depending on tested cell line and experimental setup. The
strongest synergism was observed on breast cancer-derived cell line MDA-MB-231/EGFP. Systemic administration
of CD::UPRT-MSC and HSVtk-MSC in combination with 5-FC and GCV inhibited growth of MDA-MB-231 induced
lung metastases.
Conclusions: Combined gene-directed enzyme/prodrug therapy mediated by MSC exerted synergic cytotoxic
effect and resulted in high therapeutic efficacy in vivo.
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Mesenchymal stromal cells (MSC) possess the tumor-
homing capability which predetermines them as suit-
able vehicles for delivery of therapeutic molecules into
sites of tumor burden [1-3]. Systemic administration of
MSC expressing prodrug-converting gene in combin-
ation with appropriate prodrug represents one of the
promising experimental approaches in cancer treat-
ment. It was demonstrated on glioblastoma, melanoma,
prostate, colon and hepatocellular carcinoma model
[4-7]. The two most widely used approaches represent
Herpes simplex virus thymidine kinase (HSVtk) in com-
bination with ganciclovir (GCV) and cytosine deami-
nase (CD) derived from bacteria or yeast combined
with 5-fluorocytosine (5-FC) (alone or fused with uracil
phosphoribosyltransferase, UPRT). Similarly to all other
treatments, also this therapeutic system is limited. As
we demonstrated previously, treatment efficacy can be
influenced by expression level of enzymes involved in
drug activation/degradation, intercellular communica-
tion or by expression of ABC transporters effluxing
toxic metabolites out of cells. We have also demon-
strated insufficient efficacy of the treatment by adipose
tissue-derived MSC (AT-MSC) expressing CD::UPRT
combined with 5-FC on adenocarcinoma-derived cell
line MDA-MB-231/EGFP in vitro. On the other hand,
this cell line was sensitive to treatment by HSVtk
expressing AT-MSC and GCV [8].
In order to improve the efficiency of the treatment we
used the combination of HSVtk/GCV and CD::UPRT/5-
FC approaches, however individual groups obtained dif-
ferent to contradictory results after combination of two
suicide genes and two prodrugs. Depending on the ex-
perimental setup they evaluated the effect as antagonis-
tic, additive or synergic.
Recently, the efficacy of combined enzyme/prodrug
treatment mediated by cellular vehicles was reported.
Improved efficiency of cell-based CD/HSVtk com-
bined therapy was demonstrated on breast cancer
model in vivo. Circumtumoral injection of human am-
niotic fluid-derived stem cells retrovirally transduced
with fusion bacterial CD-HSVtk gene resulted in
breast tumor suppression maintaining the original
breast tissue structures [9]. Intravenously adminis-
tered neural stem cells (NSC) expressing CD and
HSVtk exerted strong bystander effect on brain
metastases derived from human lung cancer cells
[10]. Potency and safety of double gene therapy medi-
ated by NSC was approved on glioblastoma models
[11,12].
In the present study, we demonstrated synergy of the
combined MSC-based gene therapy and significant
therapeutic effect on experimental lung metastases
induced by MDA-MB-231/EGFP cell line.Material and methods
Chemicals
All chemicals were purchased from Sigma (St Louis,
MO, USA), if not stated otherwise.
Cells
Human breast adenocarcinoma cell lines MDA-MB-231
(ATCC® Number HTB-26™), T47D (ATCC Number®
HTB-133™) and melanoma cells A375 were cultured in
high-glucose (4500 mg/ml) Dulbecco’s modified Eagle
medium (DMEM, PAA Laboratories GmbH) supple-
mented with 7% fetal bovine serum (FBS, Biochrom
AG), gentamicine 10 μg/ml, and 2 mM glutamine.
AT-MSC were isolated by plastic adherence technique
as described previously [7]. Cells were cultured in low
glucose DMEM (1000 mg/ml) (PAA Laboratories
GmbH) with GlutamMAX™ (PAA Laboratories GmbH)
supplemented with 5% HyClone® AdvanceSTEM™ Mes-
enchymal Stem Cell Growth Supplement (Thermo Sci-
entific) 5% FCS and gentamicine 10 μg/ml. AT-MSC
were characterized by flow cytometry using MSC pheno-
typing kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
and by differentiation as stated elsewhere [7]. Four isolates
of AT-MSC were used in this study.
Evaluation of gap-junctional intercellular communication
GJIC was detected by a fluorescent dye transfer assay
evaluated by flow cytometry as described previously [13]
with slight modification. Tumor cells were trypsinized,
washed twice with PBS and stained with 5 μl of Vybrant
DiI (Invitrogen, Carlsbad, CA) in 1 ml PBS per 1×106
cells for 20 min at 37°C. Monolayer of AT-MSC was
washed twice with PBS and labelled with 1 μM Calcein
AM (Invitrogen Carlsbad, CA) for 20 min at 37°C. Cells
were washed three times in PBS, trypsinized and mixed
in a ratio 1:1 with T47D, seeded on 24-well plate
(100,000 cells/well) for 24 hours coculture.
Retroviral transduction
Replication-defective retroviral vectors based on Moloney
murine leukemia virus (MMLV) were used for gene
transfer as described previously [8]. CD::UPRT gene
carrying vector pST2 [7] and vector pAPtk coding
HSVtk [13] were used for preparation of therapeutic
AT-MSC. Construct pAP-EGFP containing gene for
enhanced green fluorescent protein (EGFP) [13] was
used for transduction of tumor cells.
Evaluation of the efficacy of combined treatment in vitro
The efficacy of the treatment was evaluated by fluori-
metric assay as described in [8]. EGFP-expressing tumor
cells were cocultured with control AT-MSC (ratio 10:2)
or with the mixture of HSVtk-MSC and CD::UPRT-MSC
(ratio 10:1:1) in black 96-well plates. The test was
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7% FCS. After 24 hours the treatment started. At the
sequential treatment the 5-FC-containing medium was
added. The next day, medium was aspired and replaced
by GCV-containing medium. Plates were incubated for
next 48 hours. Medium containing both prodrugs was
added at the same time at the simultaneous treatment.
Cells were cultured for next 72 or 120 hours. Before
evaluation, the cells were washed three times with PBS.
Measurement was performed in PBS containing 0.2%
Nonidet P40. Assay was performed in quadruplicates,
results were expressed as % of relative fluorescence
(average ± standard deviation). Proliferation of cells in
medium without prodrugs was set to 100%. Combin-
ation effect of two GDEPT approaches was calculated
according to Chou [14].
Briefly, for median-effect plots, log (fa/fu) was plotted
against log (D), where fa represents affected fraction
(proportion of dead cells), fu unaffected fraction (viable
cells), and D represents the concentration of the pro-
drug(s). Combination index (CI) was computed for every
affected fraction (fa): CI < 1 represents synergism, CI = 1
represents additivity, antagonism is defined with CI > 1.
Calcusyn software was used for analysis [15].
Metastases induction and treatment in vivo
Six to eight weeks old SCID/bg mice were used in
accordance with the institutional guidelines under the
approved protocols. Lungs’ xenografts were induced by
1.5×106 MDA-MB-231/EGFP cells resuspended in
100 μl PBS and administered into tail vein. Mice were
randomly divided into groups according to the treat-
ment. For evaluation of the ability of AT-MSC to
colonize the lung tissue, 1×106 of AT-MSC was fluores-
cently stained with Vybrant DiI solution (Invitrogen,
Carlsbad, CA) in 1 ml of PBS for 20 min at 37°C.
Therapeutic (CD::UPRT-MSC, HSVtk-MSC or mixture
of both in ratio 1:1) or control AT-MSC were adminis-
tered intravenously into tail vein (1×106 cells in 150 μl
PBS) 9 days after the injection of the tumor cells.
Treated animals received daily dose of 500 mg 5-FC/kg/
day i.p (Ancotil, Valeant, Poland) and/or 50 mg/kg/day
of GCV (Cymevene, Roche, Montreal, CA) for 14 days.
Prodrugs were administered in two injections concomi-






β GLOBIN probe 3′-BHQ-1cells administration, when the control – untreated animals
had to be euthanized.Detection of tumor cells in lungs by flow cytometry
Lung tissue was homogenized using gentleMACS Disso-
ciator (Miltenyi Biotec) in the presence of 0.05% trypsin-
EDTA (Gibco). Suspension was subsequently incubated
at 37°C for 20 min and once again homogenized by gen-
tleMACS. The cells were filtered through 30 μm filters,
stained with DAPI, or 7AAD and analyzed by BD FACS-
CantoII™ analyzer equipped with BD FASCDiva™ soft-
ware. One hundred thousand events were recorded. The
FCSExpress software was used for evaluation.DNA extraction and qPCR analysis
Genomic DNA was isolated from gentleMACS homoge-
nized lung tissue as stated above. NucleoSpin® Tissue
isolation kit (Macherey Nagel, Düren, Germany) was
used for DNA isolation. We proceeded according to the
manufacturer’s instructions. DNA analyses were per-
formed by qPCR in Maxima probe qPCR master mix
(Fermentas, Germany) using thermocycler CFX 96
(Bio-Rad, USA). One hundred and fifty ng of purified
DNA from tested tissues was amplified using specific
primers and probes (Table 1) in duplex quantitative
PCR: Pre-treatment 50°C 2 minutes, initial denatur-
ation 95°C 10 minutes followed by 50 cycles at 95°C for
20 seconds, 60°C 1 minute and then the plate was read.
Final annealing was at 60°C for 10 minutes followed by
cooling step to 7°C.
The mouse Rapsyn (receptor-associated protein at the
synapse) gene was used as an internal control. The
quantity of PCR product was calculated by Ct value. The
positive control DNA was isolated from human cells
MDA-MB-231/EGFP. DNA isolated from the mouse
cell line NIH/3T3 (ATCC® CRL-1658™) was used as a
negative control.
Evaluation of human specificity of β-globin amplifica-
tion was demonstrated using 2-fold dilution for 100 ng
to 0 ng human gDNA per assay in PCR grade water and
in 0 to 100 ng murine gDNA per assay. The quantity of
human gDNA was calculated according to the calibra-
tion curve prepared as stated above. The amount of
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Formalin fixed, paraffin embedded lung tissues were cut
into 5 μm thick sections, stained with hematoxylin/eosin
and evaluated by light microscopy. Immunohistochemi-
cal staining was performed to detect EGFP expressed in
tumor cells. Slides were deparaffinized and rehydrated in
phosphate buffered saline solution (10 mM, pH 7.2). The
tissue epitopes were demasked using the automated water
bath heating process in Dako PT Link (Dako, Glostrup,
Denmark); the slides were incubated in pH 6.0 citrate re-
trieval buffer at 98°C for 20 minutes. The slides were sub-
sequently incubated for 60 minutes at room temperature
with the primary rabbit polyclonal antibody against GFP
(Abcam, anti-GFP, ab290) diluted 1:500 in Dako REAL
antibody diluent (Dako, Glostrup, Denmark) and immuno-
stained using anti-mouse/anti-rabbit immuno-peroxidase
polymer (EnVision FLEX/HRP, Dako, Glostrup, Denmark)
for 30 minutes at room temperature, according to the
manufacturer’s instructions. For visualization, the slides
were reacted with diaminobenzidine substrate-chromogen
solution (DAB, Dako, Glostrup, Denmark) for 5 minutes.
Finally, the slides were counterstained with hematoxylin.
Statistical analysis
The Mann Whitney test (comparison of two groups) and
Kruskal-Wallis test (comparison of three groups) were
used for statistical analysis. The data were analyzed by
GraphPad Prism® software (LA Jolla, CA). The value of
p < 0.05 was considered statistically significant.
Results
Sequential treatment by combined cell-based GDEPT
exerts synergic effect on tumor cells in vitro
We decided to combine two approaches of MSC-
mediated GDEPT in order to improve the efficiency of the
treatment. Since the efficacy of the HSVtk/GCV approachFigure 1 Evaluation of the functional GJIC between breast cancer-der
cells were stained with DiI, AT-MSC were stained with Calcein AM. A: T47D
B: T47D cells and AT-MSC cocultured for 24 h. R1: DiI-positive T47D cells; R
gap junctions; R3: Calcein AM-positive AT-MSC;depends on a functional intercellular gap-junctional com-
munication (GJIC) [13], only cell lines with functional
GJIC (MDA-MB-231, A375 and T47D) were used in this
study [[8]; Figure 1].
We performed sequential treatment initially, because
we proceeded from the hypothesis that depletion of
deoxynucleotide triphosphates (dNTP) pools by cytosine
deaminase and 5-FC is important for synergic cooper-
ation of CD/5-FC and HSVtk/GCV approaches [16].
Tumor cells were cultured in the presence of thera-
peutic cells in various concentrations of prodrug(s), and
the mutual cooperation of therapeutic systems was eval-
uated. The affected fraction (fa; proportion of dead cells)
was calculated, dose-effect curves and median-effect plots
were created from obtained data. The course of lines in a
median-effect plot expressed the mutual interactions
between tested therapeutic systems. It was created by
plotting x = log(D) versus y = log(fa/fu) [D = dose of drug
(s); fa = fraction affected (fa = 1- % of viable cells/100 in
our case); fu = fraction unaffected (% of viable cells/100).
It linearized the sigmoidal dose-effect curves which
express the dependence of the effect (fa) on dose of the
drug. Parallel lines of median-effect plot indicate that
drugs are mutually exclusive, convergent lines mean that
systems are mutually non-exclusive, they act in different
pathways and affect different targets.
According to the course of lines in median-effect
plots, cooperation of CD::UPRT-MSC/5-FC and HSVtk-
MSC/GCV systems was evaluated as mutually nonexclu-
sive. Lines expressing the efficacy of particular systems
(CD::UPRT/5-FC or HSVtk/GCV) were convergent and
thus indicate that active metabolites of 5-FC and GCV
affect different pathways (Figure 2).
We have previously demonstrated the low efficacy of
CD::UPRT-MSC/5-FC treatment on MDA-MB-231/
EGFP cells [IC50 5-FC = 110 μg/ml as published in [8]]ived T47D cells and AT-MSC based on Calcein AM transfer. Tumor
cells and AT-MSC were mixed immediately before measurement.
2: DiI-positive T47D cell which received Calcein AM from AT-MSC via
Figure 2 Median-effect plots demonstrate that cooperation of CD::UPRT/5-FC and HSVtk-MSC/GCV systems is mutually nonexclusive.
EGFP-expressing tumor cells were mixed with CD::UPRT-MSC and HSVtk-MSC in ratio 10:1:1 and treated by 5-FC and/or GCV. Data obtained by
fluorimetric assay were subsequently analyzed by Calcusyn software. The particular approaches affect different pathways, because the lines
representing the efficacy of CD::UPRT-MSC and HSVtk-MSC approaches are convergent. Log(D) = log of dose – concentration of particular prodrugs;
log(fa/fu) = log (proportion of dead cells/proportion of viable cells).
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GCV approach [IC50 GCV = 0.06 μg/ml as published in
[8]] Despite the low IC50 GCV we were not able to com-
pletely eliminate tumor cells from the coculture [8]. In
order to improve the cytotoxic effect we applied sequen-
tial treatment by 5-FC and GCV on direct coculture of
MDA-MB-231/EGFP cells and mixture of CD::UPRT
and HSVtk expressing AT-MSC. We observed significant
synergy in vitro (Figure 3A; B; Additional file 1: Table
S1). All of the 15 used combinations of GCV and 5-FC
concentrations exerted synergic effect on tumor cells as
documented by the value of combination index (CI).
The synergy was stronger at higher concentrations
(1–100 μg/ml) of GCV (Additional file 1: Table S1).
In order to evaluate if the synergy occurs also in cells
responding in opposite manner - sensitive to CD::UPRT-
MSC/5-FC and resistant to HSVtk-MSC/GCV treat-
ment, we performed this assay on melanoma-derived
A375/EGFP cell line [IC50 5-FC = 3.07 μg/ml; IC50 GCV =
177.02 μg/ml as published in [8]]. The effect was syner-
gic in general, although it was less pronounced in com-
parison to the MDA-MB-231/EGFP cells (Figure 3C; D;
Additional file 1: Table S1).
The breast cancer-derived cell line T47D/EGFP was
relatively sensitive to the single enzyme/prodrug treat-
ment (IC50 5-FC = 13.83 μg/ml; IC50 GCV = 3.36 μg/ml) at
72 hours-long treatment (Additional file 2: Figure S1).
We observed antagonistic to synergic effect using the
identical setup of the experiment. In general, the cooper-
ation of two systems was antagonistic at low concentra-
tions of 5-FC (0.5 μg/ml), and rather synergic at higher
concentrations of 5-FC (Figure 3E; F, Additional file 1:
Table S1). The statistical analysis of combination indexes
(Figure 3B, D and F; Additional file 1: Table S1) by
Kruskal-Wallis test showed that there was a significant
difference between cell lines used in this study (p =
0.0498). The extent of synergy observed in MDA-MB-
231 cells was significantly higher than in A375 cells (p =
0.0086) as evaluated by Mann–Whitney test.Since we planned to evaluate the efficacy of the treat-
ment in vivo, where it would be difficult to achieve the
sequential dosage of particular prodrugs due to their
pharmacokinetics, we tested if the synergy occurs also at
simultaneous treatment. Contrary to the sequential
treatment the synergic effect was suppressed at short-
term treatment (Figure 4A-B). The statistical analysis
confirmed significant difference (p < 0.0001) in cooper-
ation of two studied systems in short-term sequential
and simultaneous setup. The prolonged simultaneous
treatment significantly increased the extent of synergy in
comparison to short-term (72 hours) treatment (p =
0.0101). The simultaneous treatment seems to be more
effective on cell lines A375 and T47D (Additional file 1:
Table S1 and Additional file 3: Figure S2), although the
differences in cooperation of particular treatments are
not significant.Systemically administered AT-MSC are able to colonize
lungs for short period of time
The ability to engraft into the lung tissue is an important
factor for interactions between the tumor cells and the
therapeutic MSC. We were able to detect fluorescently
labelled AT-MSC up to seven days after systemic admin-
istration (Figure 5B). Approximately 4% of viable cells
were positive for DiI Fluorescent dye.Combined treatment by genetically engineered AT-MSC
exerts synergy on lung metastases model
We established an experimental breast cancer-derived
lung metastases model on SCID/bg mice. Tumor cells
were detectable 10 days after the intravenous inoculation
by flow cytometry (0.21% of EGFP positive cells) as well
as by qPCR (7.97 ng of human DNA/150 ng of total
DNA). Flow cytometric analysis showed that 73% (11
out of 15) animals from untreated group and 81% (9 out
of 11) mice from group which received untransduced
AT-MSC are positive for living, EGFP expressing tumor
Figure 3 Synergy of the short-time (72 hrs.) sequential combined enzyme/prodrug treatment in vitro. A; C; E: Fluorimetric assay was used
for evaluation of the efficacy of the treatment. Relative fluorescence corresponds to the proportion of viable cells. Fluorescence in cocultures
without prodrugs was set to 100% by default. Results are presented as mean of quadruplicates. SD are stated in the tables below charts.
B; D; F: Data obtained by fluorimetric assay were subsequently analyzed by Calcusyn software, and Fa-CI plots were created – CI (combination
index) on the y-axis is a function of effect level (fraction affected, fa) on the x-axis (fa = 1 - % of viable cells/100). Plots display synergism (CI < 1),
additivity (CI = 1) or antagonism (CI > 1) for the entire spectrum of effects [14].
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Figure 4 Effect of the simultaneous combined enzyme/prodrug treatment in vitro. A; C: Fluorimetric assay was used for evaluation of the
efficacy of the treatment. Relative fluorescence corresponds to the proportion of viable cells. Fluorescence in cocultures without prodrugs was set
to 100% by default. Results are presented as mean of quadruplicates. SD are stated in the tables below charts. B; D: Data obtained by fluorimetric
assay were subsequently analyzed by Calcusyn software, and Fa-CI plots were created - CI on the y-axis is a function of effect level (fraction affected, fa)
on the x-axis (fa = 1 - % of viable cells/100). Plots display synergism (CI < 1), additivity (CI = 1) or antagonism (CI > 1) for the entire spectrum of effects [14].
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cific sequences in all animals in both control groups.
Single as well as combined therapy was applied on ex-
perimental tumor-bearing animals (Figure 5A). We did not
observe the therapeutic effect of CD::UPRT-MSC/5-FC
therapy. The flow cytometric analysis of single cell suspen-
sion prepared from lungs of experimental mice revealed
that proportion of EGFP-positive cells in lungs of 5-FC
treated mice was even higher than in mice which received
AT-MSC without subsequent prodrug treatment (median
4.45% vs 13.76% of EGFP positive cells in lungs; Figure 5C).
The treatment with systemically administered HSVtk-
MSC and GCV led to decreased occurrence of the
tumor cells in lungs (median 0.4% of EGFP-positive cells
in lungs). Flow cytometric analysis revealed that three
out of six mice were negative for EGFP-expressing MDA-MB-231 cells. Low concentrations of human β-globin se-
quences were detected by qPCR (median 0.78 ng of human
β-globin/150 ng total DNA). Systemically co-administered
CD::UPRT-MSC and HSVtk-MSC in combination with
simultaneous treatment with 5-FC and GCV prevented
proliferation of MDA-MB-231/EGFP cells in mouse lungs.
The lungs were analyzed seven to ten days after the finish-
ing of the treatment. None out of 12 experimental animals
was positive for EGFP-expressing cells as evaluated by flow
cytometry (Figure 5D). Three mice were negative for hu-
man β-globin sequences, low amount of human sequences
(median 0.38 ng of human β-globin/150 ng total DNA)
was detected in rest of the animals in the group.
The summary of flow cytometric analysis is stated in
Figure 5E. The double gene therapy mediated by AT-MSC
significantly inhibited growth of experimental metastases
Figure 5 Efficacy of the treatment in vivo. Experimental metastases were induced by intravenous injection of MDA-MB-231/EGFP cells. The
presence of human cells in lungs was evaluated by flow cytometry (B-E) and by qPCR (F). A: Time line of in vivo treatment. B: Ability of intravenously
administered fluorescently labeled AT-MSC to home into mouse lungs. C: Presence of the EFGP-positive tumor cells in lung tissue in untreated mouse
which received only MDA-MB-231/EGFP cells (an example is presented, we detected 0.28 – 41.6% of viable EGFP-positive cells in mouse lungs, median
4.45). D: Absence of EGFP-expressing cells in mouse which received combined GDEPT mediated by engineered AT-MSC. E: Summary table of flow
cytometric evaluation of the efficacy of individual treatment approaches. F: Molecular analysis of lungs. Human β-globin was detected and the amount
was calculated according to 150 ng of total DNA. Highly significant difference (p < 0.0001) in amount of human DNA between untreated and double
treated animals was detected.
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cancer cells in lungs of double GDEPT-treated animals
was confirmed by histological (hematoxylin eosin staining)
and immunohistochemical (EGFP detection) staining.
(Figure 6A, B, C and D).
Discussion
The efficacy of GDEPT mediated by MSC derived from
various sources has been proven in many preclinical
studies. Obstacles connected with (non)viral vectorssuch as low transgene expression or inefficient penetra-
tion into target tissue have been eliminated by the use
of MSC or neural progenitors as delivery vehicles. Sys-
temically administered therapeutic MSC were reason-
ably used for the treatment of many types of tumors
[rev. in [17-19]].
On the other hand, we demonstrated that various
tumor cell lines differ in the response to CD::UPRT-
MSC/5-FC or HSVtk-MSC/GCV treatment depending
on the expression of enzymes of nucleotide metabolism
Figure 6 Histological and immunohistochemical analysis of
mouse tissue. A: Lung section from untreated tumor-bearing animal.
Hematoxylin/eosin staining, original magnification × 25. B: Detection
of EGFP-expressing tumor cells in lung of untreated animal.
Immunohistochemical reaction with anti-EGFP polyclonal antibody,
original magnification × 200, visualization with 3,3′-diaminobenzidine.
C: Lung section of animal treated with combined GDEPT. Hematoxylin/
eosin staining, original magnification × 25. D: No EGFP detection in
lung of double treated animal. Immunohistochemical reaction with
anti-EGFP polyclonal antibody. Original magnification × 200, visualization
with 3,3′-diaminobenzidine.
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(non)viral vectors, it was shown that combined en-
zyme/prodrug treatment can improve the treatment
efficacy [16,20,21].
In various studies, the combination of CD/5-FC and
HSVtk/GCV approaches has been described as synergic
[16,22] additive [23] or even antagonistic, suggesting
negative interactions between CD/5-FC and HSVtk/
GCV systems [24].
Slight synergistic cytotoxicity on 9L gliosarcoma cells
retrovirally transduced by E.coli CD/HSVtk fusion gene
was demonstrated by simultaneous treatment of transgene-
expressing cells with their specific prodrugs. The tox-
icity was two-fold higher when expected if the cytotoxic
effect of each prodrug was purely additive. Moreover,
combined enzyme/prodrug treatment significantly in-
creased the radiosensitivity of tumor cells [25].
Uckert et al. observed additive rather than a synergic
effect on CD/HSVtk cotransfected TS/A cells in vitro.
They supposed that the additive effect could be caused
by high sensitivity of TS/A cells to CD/5-FC treatment
alone, and addition of HSVtk could only slightly improve
the cytotoxic effect [23].
In our study, we used the melanoma cell line A375
which was highly sensitive to CD:UPRT-MSC/5-FC sys-
tem. The effect of combined treatment was less synergic
in comparison to the MDA-MB-231/EGFP cell line, with
low sensitivity to the CD::UPRT-MSC/5-FC single treat-
ment. The lower extent of synergy might be caused by
high sensitivity to CD::UPRT-MSC/5-FC approach.Significant synergy was achieved by combined treat-
ment of rat gliosarcoma cell line 9L. Detailed analysis
by the isobologram method of Loewe and the multiple
drug-effect analysis method of Chou–Talalay revealed
cooperation of CD/5-FC and HSVtk/GCV systems in
enzymes-expressing cells as well as in the bystander -
non-transfected cells. The synergy was proved also on
subcutaneous xenotransplants in vivo [22].
Boucher et al. observed synergy of combined treat-
ment on prostate carcinoma cells DU145. He put em-
phasis on sequential treatment, supposing importance of
CD/5-FC preincubation leading to alteration in dNTP
pools which can modulate the incorporation of phos-
phorylated GCV into DNA [16].
AT-MSC can home to the tumor and become an inte-
gral part of its stromal compartment [rev. in [26]]. This
feature provides an opportunity to use them as targeted
delivery vehicles for GDEPT [rev.in [19]].
Recently, additive cytotoxic effect of human amniotic
fluid-derived stem cells (hAFSC) transfected with bacterial
CD::HSVtk fusion gene on MDA-MB-231 cells was
described [9]. They observed significant therapeutic
effect on athymic mice bearing MDA-MB-231-derived
xenografts. In their setup, simultaneous treatment was
more efficient in comparison to the sequential 5-FC and
GCV treatment, but only one concentration of prodrugs
was used for evaluation of the cytotoxicity in vitro (5-FC
500 μg/ml, GCV 1 μg/ml), ratio of target/therapeutic
cells was 1:2 [9]. We applied gradient concentration of
prodrugs and their combination on cocultures consisting
of tumor and therapeutic cells in ratio 5:1. Our experi-
ments performed on MDA-MB-231/EGFP cells revealed
strong bystander synergy mediated by genetically engi-
neered AT-MSC. Even the synergy was most substantial
out of three lines used in our study. The differences in
the findings can be caused by different setup of experi-
ments as well as by different suicide genes. Yeast cyto-
sine deaminase is superior to its bacterial counterpart in
5-FC conversion [27]. Moreover, we have used yeast
cytosine deaminase fused with uracil phosphoribosyl-
transferase which even accelerates the conversion of
5-FC to toxic metabolites [28].
In our experimental setup we confirmed observation
of Boucher et al. [16] that sequential treatment (single
treatment with CD/5-FC followed by HSVtk/GCV) leads
to synergic cooperation of CD and HSVtk. We suppose
that the final outcome of in vitro studies partially de-
pends on the setup of the experiment, duration of the
treatment and prodrug concentration. When we used
too high concentrations of prodrugs in combination, the
synergic effect was suppressed (data not shown).
The sensitivity of tumor cells to the single treatment
by CD(::UPRT)/5-FC or HSVtk/GCV probably also con-
tributes to the extent of synergy. We performed double
Matuskova et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:33 Page 10 of 11treatment on three tumor cell lines with different
sensitivity to the particular approaches, and we observed
different response.
Boucher et al. [16] supposed that prolonged adminis-
tration of prodrugs could contribute to the synergy in
simultaneous (concurrent) treatment, as described by
Aghi et al. [22], allowing the depletion of dNTPs pools.
We demonstrated that prolonged simultaneous treat-
ment led to synergic cooperation of therapeutic ap-
proaches. We used long-term simultaneous treatment
in vivo. We applied both types of therapeutic cells in
two injections daily for two weeks. In order to minimize
the stress of experimental animals both prodrugs were
also administered at the same time. Maximal tolerable
doses of prodrugs were administered intraperitoneally.
Two recent papers [10,11] described therapeutic effect
of NSC coexpressing CD and HSVtk on tumor cells
in vitro and in vivo. In the later study which focused on
the safety of this approach, they demonstrated that
therapeutic NSC expressing two prodrug-converting
genes showed lower proliferation and viability in com-
parison to the CD-expressing NSC thus exerting in-
creased safety of this approach. On the other hand, they
admitted that therapeutic effect might be limited. As
demonstrated in our previous study [8], engineered AT-
MSC respond by suicide effect if they are treated with
appropriate prodrug. We suppose that the use of the
mixture of therapeutic AT-MSC expressing CD::UPRT
or HSVtk could prolong the survival of therapeutic MSC
and enable to improve the therapeutic effect.
Conclusion
Although the extent of the synergy of combined GDEPT
mediated by MSC depends on the sensitivity of tumor
cells to the particular approach and on the experimental
setup, cooperation of CD::UPRT-MSC and HSVtk-MSC
exerted synergic cytotoxic effect on human breast
adenocarcinoma cells MDA-MB-231/EGFP in vitro. Sys-
temic combined treatment confirmed the efficacy of this
approach by inhibition of proliferation of systemically
administered MDA-MB-231/EGFP cells in mouse lungs.
Additional files
Additional file 1: Table S1. Comparison of the effect of combined
treatment on three cells lines used in this study.
Additional file 2: Figure S1. Efficacy of the simple enzyme/prodrug
treatment by engineered AT-MSC on T47D cells. Cells were cocultured
with CD::UPRT-MSC or with HSVtk-MSC for 48 hours. Results are expressed
as mean ± SD. A: treatment with CD::UPRT-MSC/5-FC. B: Treatment with
HSVtk-MSC/GCV.
Additional file 3: Figure S2. Effect of the simultaneous enzyme/prodrug
treatment in vitro. Cells were treated for 72 hours (A; B; E; F) or for 120 hours
(C; D; G; H). A; C; E; G: Fluorimetric assay was used for evaluation of the
efficacy of the treatment. Relative fluorescence corresponds to theproportion of viable cells. Fluorescence in cocultures without prodrugs
was set to 100% by default. Results are presented as mean of quadruplicates.
SD are stated in the tables below charts. B; D; F; H: Data obtained by
fluorimetric assay were subsequently analyzed by Calcusyn software, and
Fa-CI plots were created - CI on the y-axis is a function of effect level (fraction
affected, fa) on the x-axis (fa = 1 - % of viable cells/100). Plots display
synergism (CI < 1), additivity (CI = 1) or antagonism (CI > 1) for the entire
spectrum of effects [14].
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